TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06167343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Description: In addition to surgical reconstruction, any structures that may have been injured concomitantly (meniscus, other ligament) will be repaired in the same surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Description: In addition to surgical reconstruction, any structures that may have been injured concomitantly (meniscus, other ligament) will be repaired in the same surgery.
Study: NCT05386758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Four 200 mg capsules administered orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Four 200 mg capsules administered orally as a single dose
Study: NCT05433415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Girls Move
Description: Goal setting and monitoring. All BGM daughters will self-monitor their progress towards PA goals using a PA device, Fitbit®. Additionally, BGM daughters will self-monitor their progress towards diet goals using a mobile application, Start Simple with My Plate®. Further, all BGM mothers will use Fitbit® and Start Simple with My Plate® for self monitoring, however, mothers' data will not be analyzed for this study. Since the daughter/ mother relationship is critical to achieving behavioral change, BGM mothers will utilize Fitbit® and Start Simple with My Plate® as a mechanism to communicate, problem solve and support daughters' behavioral goals.BGM is situated within the contexts of environmental, cultural, interpersonal, and developmental factors impacted by structural racism. Intentionally engaging mothers and daughters in an asset based program provides a framework for mothers to model responses to structural racism i.e. racial socialization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Black Girls Move
Description: Goal setting and monitoring. All BGM daughters will self-monitor their progress towards PA goals using a PA device, Fitbit®. Additionally, BGM daughters will self-monitor their progress towards diet goals using a mobile application, Start Simple with My Plate®. Further, all BGM mothers will use Fitbit® and Start Simple with My Plate® for self monitoring, however, mothers' data will not be analyzed for this study. Since the daughter/ mother relationship is critical to achieving behavioral change, BGM mothers will utilize Fitbit® and Start Simple with My Plate® as a mechanism to communicate, problem solve and support daughters' behavioral goals.BGM is situated within the contexts of environmental, cultural, interpersonal, and developmental factors impacted by structural racism. Intentionally engaging mothers and daughters in an asset based program provides a framework for mothers to model responses to structural racism i.e. racial socialization.
Study: NCT05840887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee osteotomy associated with meniscal allograft transplantation
Description: Patients will undergo knee osteotomy associated with meniscal allograft transplantation, which will be implanted by arthroscopic technique with body fixation by all-inside and transosseous sutures to the posterior horn and if necessary to the anterior horn.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee osteotomy
Description: Knee osteotomy
Study: NCT03204357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Autologous whole Blood
Description: Subjects randomized this arm will receive fresh autologous whole blood

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Expectant management of bleeding
Description: the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
Study: NCT04280289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol extract
Description: The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials
Study: NCT06588647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Participation after Stroke Self-Management Program (IPASS)
Description: The IPASS-R program is a group-based self-management intervention that aims to improve problem-solving, action-planning, and resource utilization skills for improved community living and participation. The Activity-Barriers-Changes-Doing-Evaluation (ABCDE) framework is a user friendly problem-solving and goal setting framework that is used repetitively in each session throughout the program. Participants are guided to identify (1) an activity that they want to improve or re-engage in (A); (2) individual and environmental barriers that hinder their engagement (B); (3) changes that they can make to deal with the barriers and improve their engagement (C); and (4) an action plan to pursue (D). After the action plan, participants come back in the next session and evaluate their performance in following through on their plans (E).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Self-Management Program (CDSMP)
Description: The program is facilitated by two trained leaders in small groups in a community setting with individuals who have chronic health problems and will follow the CDSMP protocol. Participants receive education on various health-related topics applicable to a range of chronic conditions, share experiences, and support one another.
Study: NCT06607757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: find arm A description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: find arm B description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant injection
Description: find arm B description
Study: NCT05273944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
Study: NCT06659978

Intervention type: DEVICE
Intervention: Device tolerance
Description: After being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed.~Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours.

Intervention type: OTHER
Intervention: Acceptability questionnaire
Description: Parental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention.
Study: NCT05273944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
Study: NCT04896736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisite tissue oxygenation-guided care
Description: The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase \>/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity
Study: NCT06659107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed reduction and fixation by K- wires
Description: Fixation by k-wires with mutual linking technique
Study: NCT06661408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group 1
Description: The women assigned to this group will be shown the newborn bath application video prepared by the researchers in groups of 2-4 people in the form of a projection presentation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group 2
Description: In groups of 2, the researcher will first explain the stages of newborn bathing application by the researcher in the form of a projection presentation, and then the pregnant women will be provided to perform the newborn bathing application on the newborn bathing model and tools simultaneously with the researcher.
Study: NCT06657859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLM101
Description: GLM101 IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLM101
Description: GLM101 IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLM101
Description: GLM101 IV infusion
Study: NCT06598670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS will be applied to the M1 area for 20 minutes with 5x7 cm electrodes. The intervention will be applied for eight weeks on alternate days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be applied to the M1 area for 20 minutes with 5x7 cm electrodes. The intervention will be applied for eight weeks on alternate days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Breathing exercises will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Breathing exercises will be performed
Study: NCT06662149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pleasant Smell
Description: The participants will be in an environment with an assumed pleasant smell while consuming the meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pleasant Smell
Description: The participants will be in an environment with an assumed pleasant smell while consuming the meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unpleasant Smell
Description: Participants will be in an environment with an assumed unpleasant smell while consuming the meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unpleasant Smell
Description: Participants will be in an environment with an assumed unpleasant smell while consuming the meal.
Study: NCT06607666

Intervention type: DRUG
Intervention: Lanreotide autogel
Description: Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs

Intervention type: DRUG
Intervention: Lanreotide autogel
Description: Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs

Intervention type: DRUG
Intervention: Lanreotide autogel
Description: Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
Study: NCT06659562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HER-096
Description: Administered as a single dose via s.c. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HER-096
Description: Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
Study: NCT06660134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Description: In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Description: In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
Study: NCT06625099

Intervention type: OTHER
Intervention: Mechanical Ventilation (MV) with Low PEEP
Description: Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and 5cmH2o PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.

Intervention type: OTHER
Intervention: Mechanical Ventilation (MV) with Optimum PEEP
Description: Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and optimum PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.~The optimum PEEP will be adjusted by titrating to the highest compliance with the open lung strategy.
Study: NCT06002906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker 1688 AIM system
Description: The Stryker 1688 AIM system used during laparoscopic surgery which is sensitive in the visible and infrared spectrum. ICG (SPY AGENT™ GREEN) is used with the SPY mode in the Stryker 1688 AIM fluorescence imaging system to perform intraoperative fluorescence angiography.
Study: NCT06235359

Intervention type: DEVICE
Group type: OTHER
Intervention: intercostal tube
Description: A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand.
Study: NCT06454890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Trop2 CAR-NK cell
Description: chemotherapy followed by Trop2 CAR-NK infusion
Study: NCT05867849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabinoid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance
Study: NCT06364449

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05553054

Intervention type: OTHER
Intervention: Quantification of IV drugs wastage
Description: Drugs are prescribed depending on physician discretion.~Specific collection bins are provided to ICU. Healthcare teams discard syringes labelled with name and dilution which have been used to prepare drugs into these bins. After 24 hours of collection, bins are analyzed by investigators.
Study: NCT04831684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be getting placebo for 8 days of dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GET73
Description: Participants will be getting GET73 for 8 days of dosing.
Study: NCT04874493

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT05914363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sealed washable floor plus behaviour change
Description: Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Description: Support for behaviour change through 'floor clubs' and the provision of printed guides

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine deworming
Description: Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine deworming
Description: Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: treatment for tungiasis
Description: Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment for tungiasis
Description: Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations
Study: NCT06042478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: Active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to remibrutinib
Description: Placebo followed by active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to omalizumab
Description: Placebo followed by active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Active comparator
Study: NCT05852210

Intervention type: OTHER
Intervention: Infrared Imaging
Description: This study will use thermal forward looking infrared (FLIR) imaging to assess the severity of Complex Regional Pain Syndrome in newly diagnosed patients.
Study: NCT05688956

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Advanced, Nutricia
Description: Per 200 mL serving size: 300 kcal, 21 g whey protein, 3 g leucine \& 10 µg Vitamin D.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise programme
Description: Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise programme
Description: Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice
Description: Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
Study: NCT05333432

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Multiparameric MRI with injection
Description: Participants have a prostate multiparametric MRI with gadolinium injection (T2, diffusion and perfusion sequences) every year.~PIRADS-V2 is used as decisional endpoint, and subjective score LIKERT as secondary analysis.~To compute sensivity and specificity, we consider LIKERT as suspicious and/or malignant (PIRADS-V2 = 3, 4 or 5) as positive.
Study: NCT05845502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SZ003 CAR-NK
Description: Drug: SZ003 CAR-NK In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8 ,2.0×10\^8 and5.0×10\^8 cells. The infusion is given every 2 weeks.
Study: NCT05345197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emicizumab
Description: This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
Study: NCT06499090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine 30 MG
Description: patients will receive orally the night before surgery the study medication and daily up to two weeks after Mirtazapine 30 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive orally the night before surgery the study medication and daily up to two weeks after placebo tablet